April 25, 2024
Bio
Pharmabcine partners with MSD for Keytruda combo therapy
[THE INVESTOR] Korea’s biotech firm Pharmabcine said on Jan. 31 that it has entered a partnership agreement with MSD to evaluate its human monoclonal antibody TTAC-0001 in combination with MSD’s anti-PD-1 therapy Keytruda in patients with recurrent glioblastoma and metastatic triple negative breast cancer.
TTAC-0001 is a fully human anti-vascular endothelial growth factor receptor 2 monoclonal antibody, associated with inhibition of tumor angiogenesis. The company completed phase 2a clinical trials of the drug candidate in patients with recurrent glioblastoma in Australia last year.
“We expect potential synergy between TTAC-0001 and Keytruda through the combination based on clinical response rates that each drug demonstrated as monotherapy,” Yoo Jin-san, CEO of PharmAbcine said in a statement.
Under the agreement, the two firms will conduct phase 1 and 2 clinical studies.
By Park Han-na (hnpark@heraldcorp.com)
TTAC-0001 is a fully human anti-vascular endothelial growth factor receptor 2 monoclonal antibody, associated with inhibition of tumor angiogenesis. The company completed phase 2a clinical trials of the drug candidate in patients with recurrent glioblastoma in Australia last year.
“We expect potential synergy between TTAC-0001 and Keytruda through the combination based on clinical response rates that each drug demonstrated as monotherapy,” Yoo Jin-san, CEO of PharmAbcine said in a statement.
Under the agreement, the two firms will conduct phase 1 and 2 clinical studies.
By Park Han-na (hnpark@heraldcorp.com)
![[From the Scene] KG Mobility poised to take next leap](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=151&simg=/content/image/2024/04/24/20240424050621_0.jpg)
